ProShares Ultra Bloomberg Natural Gas

Altimmune Inc. Common Stock

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

ProShares UltraShort Silver

Direxion Daily Semicondct Bull 3X ETF

United States Natural Gas

Direxion Daily Gold Miners Bear 3X ETF

GraniteShares 1.5x Long META Daily ETF

Volatility Shares Trust 2x Ether ETF

Direxion Daily Technology Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners 3X Leveraged ETN

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Ultra Silver

ProShares Ultra VIX Short-Term Futures

Direxion Daily Gold Miners Bull 3X ETF

Direxion Technology Bear 3X Shares

ProShares Ultra DJ-AIG Crude Oi

VanEck Vectors Junior Gold Miners ETF

Theriva Biologics Inc. Common Stock

Hyperscale Data Inc. Common Stock

Porch Group Inc. Common Stock

Charles River Laboratories International Inc. Common Stock

Resideo Technologies Inc. Common Stock

Granite Point Mortgage Trust Inc. Common Stock

Phio Pharmaceuticals Corp. Common Stock

Bioventus Inc. Class A Common Stock

Walt Disney Company (The) Common Stock

Fastly Inc. Class A Common Stock

New Century Logistics (BVI) Limited Ordinary Shares

MicroAlgo Inc. Ordinary Shares

IBO (Listing Market - NYSE Amex Network B F)

Fortinet Inc. Common Stock

Cleveland-Cliffs Inc. Common Stock

Arm Holdings plc American Depositary Shares

Upstart Holdings Inc. Common stock

Marvell Technology Inc. Common Stock

Select Energy Services Inc. Class A Common Stock

Energizer Holdings Inc. Common Stock

Click here to get full coverage on Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4% - Yahoo Finance

Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4%  Yahoo Finance

Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4% - Yahoo Finance

Click here to get full coverage on Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value - Business Wire

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value  Business Wire

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value - Business Wire

Click here to get full coverage on Charles River (CRL) Stock Upgraded Following Strong Q1 Results | - GuruFocus

Charles River (CRL) Stock Upgraded Following Strong Q1 Results |  GuruFocus

Charles River (CRL) Stock Upgraded Following Strong Q1 Results | - GuruFocus

Click here to get full coverage on CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up - TradingView

CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up  TradingView

CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up - TradingView

Click here to get full coverage on Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics - Nasdaq

Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics  Nasdaq

Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics - Nasdaq

Click here to get full coverage on Charles River stock surges after Q1 beat (CRL:NYSE) - Seeking Alpha

Charles River stock surges after Q1 beat (CRL:NYSE)  Seeking Alpha

Charles River stock surges after Q1 beat (CRL:NYSE) - Seeking Alpha

Click here to get full coverage on Charles River Laboratories Announces First-Quarter 2025 Results - Stock Titan

Charles River Laboratories Announces First-Quarter 2025 Results  Stock Titan

Charles River Laboratories Announces First-Quarter 2025 Results - Stock Titan

Click here to get full coverage on Charles River Laboratories International Q1 2025 Earnings Call Transcript - MarketBeat

Charles River Laboratories International Q1 2025 Earnings Call Transcript  MarketBeat

Charles River Laboratories International Q1 2025 Earnings Call Transcript - MarketBeat

Click here to get full coverage on Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance

Why Are Charles River Laboratories (CRL) Shares Soaring Today  Yahoo Finance

Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance

Click here to get full coverage on Charles River Laboratories (CRL) Adjusts 2025 Guidance Amid Revenue Decline - GuruFocus

Charles River Laboratories (CRL) Adjusts 2025 Guidance Amid Revenue Decline  GuruFocus

Charles River Laboratories (CRL) Adjusts 2025 Guidance Amid Revenue Decline - GuruFocus

Click here to get full coverage on Charles River Laboratories (CRL) Surges on Strong Q1 Results and Upgraded Outlook - GuruFocus

Charles River Laboratories (CRL) Surges on Strong Q1 Results and Upgraded Outlook  GuruFocus

Charles River Laboratories (CRL) Surges on Strong Q1 Results and Upgraded Outlook - GuruFocus

Click here to get full coverage on Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates  Yahoo Finance

Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Charles River Laboratories (CRL) Shares Surge Following Strategic Review Announcement - GuruFocus

Charles River Laboratories (CRL) Shares Surge Following Strategic Review Announcement  GuruFocus

Charles River Laboratories (CRL) Shares Surge Following Strategic Review Announcement - GuruFocus

Click here to get full coverage on CRL Sees Q1 Revenue Boost, Raises 2025 Guidance | CRL Stock News - GuruFocus

CRL Sees Q1 Revenue Boost, Raises 2025 Guidance | CRL Stock News  GuruFocus

CRL Sees Q1 Revenue Boost, Raises 2025 Guidance | CRL Stock News - GuruFocus

Click here to get full coverage on Charles River (CRL) Announces Board Restructure and Strategic Review | CRL Stock News - GuruFocus

Charles River (CRL) Announces Board Restructure and Strategic Review | CRL Stock News  GuruFocus

Charles River (CRL) Announces Board Restructure and Strategic Review | CRL Stock News - GuruFocus

Click here to get full coverage on CRL Revises FY Revenue Growth Forecast Following DSA Segment Improvement | CRL Stock News - GuruFocus

CRL Revises FY Revenue Growth Forecast Following DSA Segment Improvement | CRL Stock News  GuruFocus

CRL Revises FY Revenue Growth Forecast Following DSA Segment Improvement | CRL Stock News - GuruFocus

Click here to get full coverage on Charles River Laboratories Announces First-Quarter 2025 Results | CRL Stock News - GuruFocus

Charles River Laboratories Announces First-Quarter 2025 Results | CRL Stock News  GuruFocus

Charles River Laboratories Announces First-Quarter 2025 Results | CRL Stock News - GuruFocus

Click here to get full coverage on Charles River Laboratories (CRL) Announces Strategic Cooperation Agreement with Elliott Management - GuruFocus

Charles River Laboratories (CRL) Announces Strategic Cooperation Agreement with Elliott Management  GuruFocus

Charles River Laboratories (CRL) Announces Strategic Cooperation Agreement with Elliott Management - GuruFocus

Click here to get full coverage on Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance

Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect  Yahoo Finance

Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance

Click here to get full coverage on Earnings Flash (CRL) Charles River Laboratories International Reports Q1 Adjusted EPS $2.34, vs. FactSet Est of $2.07 - marketscreener.com

Earnings Flash (CRL) Charles River Laboratories International Reports Q1 Adjusted EPS $2.34, vs. FactSet Est of $2.07  marketscreener.com

Earnings Flash (CRL) Charles River Laboratories International Reports Q1 Adjusted EPS $2.34, vs. FactSet Est of $2.07 - marketscreener.com

Click here to get full coverage on FDA Issues CRL to TLX101-CDx for Glioma Imaging - OncLive

FDA Issues CRL to TLX101-CDx for Glioma Imaging  OncLive

FDA Issues CRL to TLX101-CDx for Glioma Imaging - OncLive

Click here to get full coverage on CRL Adds Matte Black Finish to Door Closer Line - Glass Magazine - NGA

CRL Adds Matte Black Finish to Door Closer Line  Glass Magazine - NGA

CRL Adds Matte Black Finish to Door Closer Line - Glass Magazine - NGA

Click here to get full coverage on Charles River Laboratories (CRL) Awaits Q1 Earnings Amid Mixed Projections - GuruFocus

Charles River Laboratories (CRL) Awaits Q1 Earnings Amid Mixed Projections  GuruFocus

Charles River Laboratories (CRL) Awaits Q1 Earnings Amid Mixed Projections - GuruFocus

Click here to get full coverage on FDA Issues CRL for Extended Dosing of Eylea HD - Managed Healthcare Executive

FDA Issues CRL for Extended Dosing of Eylea HD  Managed Healthcare Executive

FDA Issues CRL for Extended Dosing of Eylea HD - Managed Healthcare Executive

Click here to get full coverage on Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Yahoo Finance

Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday?  Yahoo Finance

Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Yahoo Finance

Click here to get full coverage on FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD - CGTLive®

FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD  CGTLive®

FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD - CGTLive®

Click here to get full coverage on Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - Yahoo Finance

Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break  Yahoo Finance

Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - Yahoo Finance

Click here to get full coverage on Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?  Yahoo Finance

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Click here to get full coverage on Another CRL Prompts Questions About Regeneron’s Regulatory Operations - insights.citeline.com

Another CRL Prompts Questions About Regeneron’s Regulatory Operations  insights.citeline.com

Another CRL Prompts Questions About Regeneron’s Regulatory Operations - insights.citeline.com

Click here to get full coverage on New Zero Shower Collection Hardware from CRL Elevates Shower Enclosure Design and Performance - Business Wire

New Zero Shower Collection Hardware from CRL Elevates Shower Enclosure Design and Performance  Business Wire

New Zero Shower Collection Hardware from CRL Elevates Shower Enclosure Design and Performance - Business Wire

Click here to get full coverage on Collegiate Rocket League Spring 2025 Preview - Rocket League

Collegiate Rocket League Spring 2025 Preview  Rocket League

Collegiate Rocket League Spring 2025 Preview - Rocket League

Click here to get full coverage on FDA Issues CRL for Govorestat Application As Treatment for Classic Galactosemia - Neurology live

FDA Issues CRL for Govorestat Application As Treatment for Classic Galactosemia  Neurology live

FDA Issues CRL for Govorestat Application As Treatment for Classic Galactosemia - Neurology live

Click here to get full coverage on FDA issues CRL for aflibercept 8 mg extended dosing for all indications - Contemporary Pediatrics

FDA issues CRL for aflibercept 8 mg extended dosing for all indications  Contemporary Pediatrics

FDA issues CRL for aflibercept 8 mg extended dosing for all indications - Contemporary Pediatrics

Click here to get full coverage on There's No Escaping Creightons Plc's (LON:CRL) Muted Revenues Despite A 31% Share Price Rise - simplywall.st

There's No Escaping Creightons Plc's (LON:CRL) Muted Revenues Despite A 31% Share Price Rise  simplywall.st

There's No Escaping Creightons Plc's (LON:CRL) Muted Revenues Despite A 31% Share Price Rise - simplywall.st

Click here to get full coverage on Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease - OncLive

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease  OncLive

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease - OncLive

Click here to get full coverage on Charles River Laboratories International, Inc. (CRL): Among the Worst Performing Stocks in S&P 500 So Far in 2025 - Yahoo Finance

Charles River Laboratories International, Inc. (CRL): Among the Worst Performing Stocks in S&P 500 So Far in 2025  Yahoo Finance

Charles River Laboratories International, Inc. (CRL): Among the Worst Performing Stocks in S&P 500 So Far in 2025 - Yahoo Finance

Click here to get full coverage on FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More - CGTLive®

FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More  CGTLive®

FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More - CGTLive®

Click here to get full coverage on Clash Royale esports is back with new CRL 2025 format - Esports Insider

Clash Royale esports is back with new CRL 2025 format  Esports Insider

Clash Royale esports is back with new CRL 2025 format - Esports Insider

Click here to get full coverage on FDA slaps CRL on Seikagaku’s BLA for condoliase - The Pharma Letter

FDA slaps CRL on Seikagaku’s BLA for condoliase  The Pharma Letter

FDA slaps CRL on Seikagaku’s BLA for condoliase - The Pharma Letter

Click here to get full coverage on Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo Finance

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?  Yahoo Finance

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo Finance

Click here to get full coverage on Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks

Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era  TipRanks

Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks

Click here to get full coverage on Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive - simplywall.st

Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive  simplywall.st

Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive - simplywall.st

Click here to get full coverage on Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for - Yahoo

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for  Yahoo

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for - Yahoo

Click here to get full coverage on FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC - Targeted Oncology

FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC  Targeted Oncology

FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC - Targeted Oncology

Click here to get full coverage on Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha

Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback  Seeking Alpha

Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha

Click here to get full coverage on OGD officials offer advice on ANDAs, post-CRL scientific meetings - Regulatory Affairs Professionals Society | RAPS

OGD officials offer advice on ANDAs, post-CRL scientific meetings  Regulatory Affairs Professionals Society | RAPS

OGD officials offer advice on ANDAs, post-CRL scientific meetings - Regulatory Affairs Professionals Society | RAPS

Click here to get full coverage on Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity  Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Click here to get full coverage on Camrelizumab Plus Rivoceranib Receives Second CRL in HCC - Oncology Nursing News

Camrelizumab Plus Rivoceranib Receives Second CRL in HCC  Oncology Nursing News

Camrelizumab Plus Rivoceranib Receives Second CRL in HCC - Oncology Nursing News

Click here to get full coverage on Another Regeneron CRL Prompts Regulatory Operations Questions - insights.citeline.com

Another Regeneron CRL Prompts Regulatory Operations Questions  insights.citeline.com

Another Regeneron CRL Prompts Regulatory Operations Questions - insights.citeline.com

Click here to get full coverage on Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Yahoo Finance

Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025  Yahoo Finance

Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Yahoo Finance

Click here to get full coverage on Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow - Yahoo Finance

Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow  Yahoo Finance

Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow - Yahoo Finance

Click here to get full coverage on Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance

Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics  Yahoo Finance

Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance

Click here to get full coverage on Should Weakness in Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st

Should Weakness in Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?  simplywall.st

Should Weakness in Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st

Click here to get full coverage on CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall - Yahoo Finance

CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall  Yahoo Finance

Charles River Laboratories (CRL)

Price Chart

Key Statistics

Technicals

About CRL

Latest News

Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4% - Yahoo Finance

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value - Business Wire

Charles River (CRL) Stock Upgraded Following Strong Q1 Results | - GuruFocus

Advanced Charts

Top Gainers

Top Losers